In Vitro and In Vivo Radiosensitizing Effect of Valproic Acid on Fractionated Irradiation
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose This study was conducted in order to validate the radiosensitization effect of valproic acid, a biologically available histone deacetylase inhibitor, for fractionated radiation. Materials and Methods Radiosensitization effect of valproic acid was tested for the A549 cell line and U87MG cell line in vitro. Fractionated irradiation of 12 Gy in four fractions was administered on D2-5 with valproic acid, 150 mg/Kg, ip, bid for six consecutive days (D1-6) to A549 and U87MG tumors implanted in BALB/c-nude mice. A growth delay curve was formulated. Results Radiosensitization effect of valproic acid was found for both cell lines; A549 at 1.5 mM and 3.0 mM concentration and U87MG at 3.0 mM concentration. In growth delay analysis, a statistically significant radiosensitization effect was observed for both tumors (p < 0.001 for both tumors). Difference for change in slope for control and valproic acid versus radiotherapy and radiotherapy plus valproic acid showed borderline significance for the U87MG cell line (p=0.065), indicating beyond additive effect, whereas this difference was statistically insignificant for A549 tumor (p=0.951), indicating additive effect. Conclusion Results of this study indicate that a radiosensitizing effect for fractionated radiotherapy of valproic acid for A549 and U87MG tumors in vivo is evident and that it may be more than additive for U87MG tumors. Further exploitation of histone deacetylase inhibitors in clinical trials is warranted.
Abstract
Purpose This study was conducted in order to validate the radiosensitization effect of valproic acid, a biologically available histone deacetylase inhibitor, for fractionated radiation. Materials and Methods Radiosensitization effect of valproic acid was tested for the A549 cell line and U87MG cell line in vitro. Fractionated irradiation of 12 Gy in four fractions was administered on D2-5 with valproic acid, 150 mg/Kg, ip, bid for six consecutive days (D1-6) to A549 and U87MG tumors implanted in BALB/c-nude mice. A growth delay curve was formulated. Results Radiosensitization effect of valproic acid was found for both cell lines; A549 at 1.5 mM and 3.0 mM concentration and U87MG at 3.0 mM concentration. In growth delay analysis, a statistically significant radiosensitization effect was observed for both tumors (p < 0.001 for both tumors). Difference for change in slope for control and valproic acid versus radiotherapy and radiotherapy plus valproic acid showed borderline significance for the U87MG cell line (p=0.065), indicating beyond additive effect, whereas this difference was statistically insignificant for A549 tumor (p=0.951), indicating additive effect. Conclusion Results of this study indicate that a radiosensitizing effect for fractionated radiotherapy of valproic acid for A549 and U87MG tumors in vivo is evident and that it may be more than additive for U87MG tumors. Further exploitation of histone deacetylase inhibitors in clinical trials is warranted.
참고문헌 (24)
- Camphausen K, "Inhibition of histone deacetylation : a strategy for tumor radiosensitization", J Clin Oncol, 25, pp.4051~4056 (2007)
- Munshi A, "Histone deacetylase inhibitors radiosensitize human melanoma cells by suppressing DNA repair activity", Clin Cancer Res, 11, pp.4912~4922 (2005)
- Kim JH, "Susceptibility and radiosensitization of human glioblastoma cells to trichostatin A, a histone deacetylase inhibitor", Int J Radiat Oncol Biol Phys, 59, pp.1174~1180 (2004)
- Flatmark K, "Radiosensitization of colorectal carcinoma cell lines by histone deacetylase inhibition", Radiat Oncol, 1, pp.25~ (2006)
- Zhang Y, "Enhancement of radiation sensitivity of human squamous carcinoma cells by histone deacetylase inhibitors", Radiat Res, 161, pp.667~674 (2004)
- Gottlicher M, "Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells", EMBO J, 20, pp.6969~6978 (2001)
- Camphausen K, "Enhancement of in vitro and in vivo tumor cell radiosensitivity by valproic acid", Int J Cancer, 114, pp.380~386 (2005)
- Karagiannis TC, "The epigenetic modifier, valproic acid, enhances radiation sensitivity", Epigenetics, 1, pp.131~137 (2006)
- Baylin SB, "Epigenetic gene silencing in cancer: a mechanism for early oncogenic pathway addiction?", Nat Rev Cancer, 6, pp.107~116 (2006)
- Esteller M, "Epigenetics provides a new generation of oncogenes and tumour-suppressor genes", Br J Cancer, 94, pp.179~183 (2006)
- De Schutter H, "Radiosensitizing potential of epigenetic anticancer drugs", Anticancer Agents Med Chem, 9, pp.99~108 (2009)
- Coyle TE, "Acute leukemia associated with valproic acid treatment: a novel mechanism for leukemogenesis?", Am J Hematol, 78, pp.256~260 (2005)
- Purrucker JC, "HDAC inhibition radiosensitizes human normal tissue cells and reduces DNA double-strand break repair capacity", Oncol Rep, 23, pp.263~269 (2010)
- Chung YL, "Antitumor histone deacetylase inhibitors suppress cutaneous radiation syndrome : implications for increasing therapeutic gain in cancer radiotherapy", Mol Cancer Ther, 3, pp.317~325 (2004)
- Paoluzzi L, "Histone deacetylase inhibitors are potent radiation protectants", Cancer Biol Ther, 3, pp.612~613 (2004)
- Chen X, "HDAC inhibitor, valproic acid, induces p53-dependent radiosensitization of colon cancer cells", Cancer Biother Radiopharm, 24, pp.689~699 (2009)
- Driever PH, "Valproic acid for the treatment of pediatric malignant glioma", Klin Padiatr, 211, pp.323~328 (1999)
- Mehta MP, "DeVita, Hellman, and Rosenberg's cancer:principles and practice of oncology", pp.1967~2032 (2008), Lippincott Williams and Wilkins
- Munshi A, "Vorinostat, a histone deacetylase inhibitor, enhances the response of human tumor cells to ionizing radiation through prolongation of gamma-H2AX foci", Mol Cancer Ther, 5, pp.1967~1974 (2006)
- Kim BK, "Radiosensitizing effect and mechanisms of action of a novel HDAC inhibitor, SK-7041", pp.2007
- Kim IA, "HDAC inhibitormediated radiosensitization in human carcinoma cells: a general phenomenon?", J Radiat Res, 51, pp.257~263 (2010)
- Hall EJ, "Radiobiology for the radiologist", pp.30~397 (2006), Lippincott Williams & Wilkins
- "Search term “valproic acid” AND “radiotherapy”" (2013)[URL]
- Chang AR, "Histone deacetylase inhibitory activity of valproic acid in glioblastoma", J Korean Soc Ther Radiol Oncol, 25, pp.s30~ (2007)